A Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness of Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects in Daily Clinical Practice (SOMACROL).
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms SOMACROL
- Sponsors Ipsen
- 27 Oct 2017 Status changed from recruiting to completed.
- 25 Jul 2017 Planned number of patients changed from 150 to 100.
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.